Rx License-Rx

TAB-3530

Improved Synthesis of Dopamine D3 Receptor Selective Antagonists / Partial Agonists

In the last decade, prescription opioid abuse and misuse has been a major contributor to mortality in the United States, resulting in a serious national public health crisis. Nearly 12 million Americans used prescription opioids nonmedically in 2018, with >67,000 people dying from an opioid overdose. The federal response to the opioid crisis includes research support toward the development of non-addictive analgesics and additional medications to treat opioid use disorders (OUD). Recently, a novel series of (R)-N-(4-(4-(3-chloro-5-ethyl-2-methoxyphenyl) piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide (8)-(R)VK4-116 have been discovered as high affinity and selective D3R (Dopamine D3 receptor) lead molecules for the treatment of opioid use disorders (OUD) by a discovery team at NIDA (NIH). Furthering the earlier work by colleagues at NIDA, NCATS scientists have developed new synthetic routes to accelerate synthesis and yields...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Neurology

Indication: Psychiatry/Mental Health

Modality: Cell/Gene Therapy

Focus tags: Neurology, Ophthalmology, Oncology, Infectious Disease, Cardiometabolic, Inflammation

Technology tags: Cell/Gene Therapy, Small Molecule

Mechanism:

Development stage: Clinical

Patent status: Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Neurology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be clinical and is associated with National Institutes of Health. The practical first use case is Psychiatry/Mental Health. Public description: In the last decade, prescription opioid abuse and misuse has been a major contributor to mortality in the United States, resulting in a serious national public health crisis. Nearly 12 million Americans used prescription opioids.

What is exciting

More mature than a typical academic invention: Prior human, regulatory, or deployment evidence can shorten diligence and make strategic buyers more comfortable.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Negatives / diligence concerns

Clinical context matters: A clinical-stage label is only useful if the trial design, population, endpoints, safety signal, and follow-on plan are strong.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: Psychiatry/Mental Health

Study design: Ocular tolerability, local PK, and small image-based proof-of-mechanism study.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.